Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and antidrug antibodies in PANAMO: a phase 3 study in critically ill,  invasively mechanically ventilated COVID-19 patients

BACKGROUND: Vilobelimab, a complement 5a (C5a)-specific monoclonal antibody, reduced mortality in critically ill COVID-19 patients in a phase 3 multicentre, randomized, double-blind, placebo-controlled study. As part of the study, vilobelimab concentrations and C5a levels as well as antidrug antibod...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Endry H. T., Vlaar, Alexander P. J., de Bruin, Sanne, Rückinger, Simon, Thielert, Claus, Habel, Maria, Guo, Renfeng, Burnett, Bruce P., Dickinson, James, Brouwer, Matthijs C., Riedemann, Niels C., van de Beek, Diederik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10277268/
https://www.ncbi.nlm.nih.gov/pubmed/37332066
http://dx.doi.org/10.1186/s40635-023-00520-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10277268/
https://www.ncbi.nlm.nih.gov/pubmed/37332066
http://dx.doi.org/10.1186/s40635-023-00520-8

Ejemplares similares